

June 5, 2017  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**SEC Filing by The Medicines Company as the Licensor of  
the Patient-controlled Pain Management Drug “SyB P-1501”**

TOKYO, Japan, June 5, 2017 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio"), in relation to the temporary suspension of new patient enrollment in the Japanese Phase 3 clinical trial of “SyB P-1501,” a drug for patient-controlled, short-term management of acute postoperative pain during hospitalization (the "Product"), reported today that The Medicines Company (Headquarters: New Jersey, U.S., "MDCO"), the licensor of the Product (through its subsidiary, Incline Therapeutics, Inc.), filed a Form 8-K with the U.S. Securities and Exchange Commission on June 2, 2017.

In MDCO's Form 8-K it is stated that MDCO commenced implementation of a workforce reduction on June 1, 2017 in connection with MDCO's discontinuation and market withdrawal of IONSYS® in the United States and the cessation of related commercialization activities (Note: the Product is marketed under the name of IONSYS® in the U.S.), while the New Drug Application for IONSYS® remains open to December 31, 2017.

Symbio will discuss with MDCO the effects of MDCO's 8-K filing on the SyB P-1501 clinical trial plan and will make a timely disclosure accordingly.

**[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

**About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.